An Bioequivalence Study of Loxoprofen Sodium Patches in Healthy Volunteers

Inclusion Criteria: * Male weight ≥50 kg, female weight ≥45 kg, body mass index (BMI) between 19.0 and 28.0 kg/m2, inclusive . * Informed consent: signed written informed consent before inclusion in the study. * The subjects are well communicated and are able to comply with the requirements of the study Exclusion Criteria: * Participated in other drug intervention studies within 90 days * Allergic to this product and excipients, or have a history of food, drug allergy or other allergic diseases (asthma, urticaria, eczema dermatitis, etc.) * Aspirin asthma * Any visible skin disorder or abnormal skin pigmentation which, in the opinion of the investigator, would interfere with the outcome of the trial. * A history of cardiovascular system, respiratory system, digestive system, urinary system, endocrine system, immune system, nervous/psychiatric system, blood and lymphatic system, and skeletal musculoskeletal system that investigator have determined to be abnormal and clinically significant * Postural hypotension, needle fainting or blood fainting history or venipuncture intolerance * Any drug that inhibits or induces liver metabolism has been used in the 30 days prior to screening. Inducers: barbiturates, carbamazepine, phenytoin sodium, glucocorticoids, omeprazole; Inhibitors: SSRI antidepressants, cimetidine, Diltiazem, nitroimidazoles, sedatives and hypnotics, verapamil, fluoroquinolones, antihistamines * Blood donation or significant blood loss (\>400 mL, except for fema…